CliffBio
small molecule

SODIUM ACETATE

SODIUM ACETATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameSODIUM ACETATE
Active ingredientSODIUM ACETATE
Strength400MEQ/100ML (4MEQ/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2017
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.